Stock listing

OTC:IDRSF Idorsia Ltd. Stock

US listing (OTC) of Idorsia Ltd. · home listing SIX Swiss:IDIA

Follow Idorsia Ltd. into a list and get an email when it puts out news.

Share price · OTC:IDRSF

$4.20 USD -0.50 (-10.6%)

Close on Nov 20, 2026

Past year +25.3% · daily closes, Nov 25, 2025 – Nov 6, 2026, adjusted for splits
Day range
$4.20 – $4.20 USDNov 20, 2026
Volume
300 sharesNov 20, 2026
Market cap
$1.13B USDAt the close on Nov 20, 2026 · price × 269.8M shares outstanding
52-week range
$3.50 – $8.19 USDLowest and highest trades, Nov 25, 2025 – Nov 20, 2026
Traded on an average day
$24,028 USDMedian day 740 shares · 8 days with no trades · last 3 months, Aug 21, 2026 – Nov 6, 2026
Idorsia Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:IDIA · Home3.586 CHF-0.254 (-6.6%)783,1653.713.723.533.84Close on Nov 20, 2026
OTC:IDRSF$4.20 USD-0.50 (-10.6%)300$4.20$4.20$4.20$4.70Close on Nov 20, 2026
Frankfurt:19T€3.926 EUR-0.366 (-8.5%)—€3.988€3.988€3.926€4.292Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 21, 2026 – Nov 6, 2026 · OTC:IDRSF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.950.000.0%$4.95$4.95$4.952,785
$4.950.000.0%$4.95$4.95$4.950
$4.950.000.0%$4.95$4.95$4.950
$4.950.000.0%$4.95$4.95$4.950
$4.950.000.0%$4.95$4.95$4.950
$4.950.000.0%$4.95$4.95$4.950
$4.95-0.43-8.0%$5.00$5.00$4.951,080
$5.380.000.0%$5.38$5.38$5.380
$5.380.000.0%$5.38$5.38$5.380
$5.380.000.0%$5.38$5.38$5.380
$5.38-0.02-0.4%$5.38$5.38$5.381,440
$5.40+0.21+4.0%$5.42$5.42$5.401,483
$5.19-0.11-2.1%$5.20$5.20$5.1926,650
$5.30-0.30-5.4%$5.30$5.30$5.30200
$5.60-0.53-8.6%$5.60$5.60$5.60150
$6.13-0.02-0.3%$6.13$6.13$6.132,992
$6.15-0.12-1.9%$6.15$6.15$6.152,000
$6.27+0.03+0.5%$6.31$6.31$6.272,000
$6.24-0.01-0.2%$6.24$6.24$6.24400
$6.25-0.25-3.8%$6.25$6.25$6.252,000
$6.50-0.75-10.3%$6.90$6.90$6.5030,938
$7.25-0.06-0.8%$7.25$7.25$7.2513,000
Ticker
OTC:IDRSF
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Idorsia Ltd. news

Idorsia Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
33 in the last 12 months · 76 in all · newest Oct 29, 2026 · oldest 2025
Calls
16 calls with a replay · 16 with a transcript · latest Jul 30, 2026
Decks
55 decks · latest Nov 4, 2026

Where Idorsia Ltd. is listed

ListingExchangeCountryCurrency
SIX Swiss:IDIA · Home listingSIX SwissSwitzerlandCHF
LSIN:0RQELSINUnited KingdomCHF
OTC:IDRSF · This pageOTCUnited StatesUSD
Lang & Schwarz:A2DTEBLang & SchwarzGermanyEUR
gettex:19TgettexGermanyEUR
LS Exchange:A2DTEBLS ExchangeGermanyEUR
BX Swiss:19TBX SwissSwitzerlandCHF
Tradegate:19TTradegateGermanyEUR
Aquis:IDIAZAquisUnited KingdomCHF
Frankfurt:19TFrankfurtGermanyEUR
Turquoise:IDIAZTurquoiseUnited KingdomCHF
Dusseldorf:19TDusseldorfGermanyEUR
Hamburg:19THamburgGermanyEUR
Munich:19TMunichGermanyEUR
Stuttgart:19TStuttgartGermanyEUR
Hanover:19THanoverGermanyEUR
Xetra:19TXetraGermanyEUR

Valuation

EV/sales 10.2× against a median of 2.7×: the highest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
2.24B CHF
P/E
Loss
EV/sales
10.2×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
79.2%
Operating margin
−106.5%
Net margin
−128.8%
Debt to equity
Negative equity
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Idorsia Ltd. · SIX:IDIAUS$1.15BUS$2.66Bn/a10.2×n/an/a−128.8%n/an/a
Zhejiang Xianju Pharmaceutical Co., Ltd. Class A · SZSE:002332US$1.24BUS$1.08B17.7×1.9×n/a1.4×12.0%0.0×n/a
Amphastar Pharmaceuticals, Inc. · NASDAQ:AMPHUS$1.20BUS$976.8M12.2×1.3×5.6×1.5×13.3%0.0×0.52
Hualan Biological Vaccine Inc. Class A · SZSE:301207US$1.16BUS$845.9M167×8.1×n/a1.5×6.6%0.0×n/a
Chongqing Lummy Pharmaceutical Co., Ltd. Class A · SZSE:300006US$1.15BUS$1.04Bn/a9.6×n/a4.5×−16.6%0.1×n/a
Harrow, Inc. · NASDAQ:HROWUS$1.14BUS$1.36Bn/a4.5×188×39.1×−9.4%10.0×1.31
Changzhou Qianhong Bio-Pharma Co., Ltd. Class A · SZSE:002550US$1.12BUS$929.9M32.3×4.1×n/a2.7×15.3%0.0×n/a
GC Biopharma Corp. · KRX:006280US$1.10BUS$1.30Bn/a0.9×13.2×1.2×−2.5%0.3×n/a
Vetoquinol SA · EURONEXT:VETOUS$1.09BUS$848.5M17.4×1.5×7.0×1.6×10.9%0.0×n/a
North China Pharmaceutical Company Ltd. Class A · SSE:600812US$1.09BUS$1.55B81.1×1.3×n/a1.3×1.1%0.8×n/a
Basilea Pharmaceutica AG · SIX:BSLNUS$1.07BUS$964.3M22.4×3.5×15.2×5.6×17.3%0.5×n/a
Median of the othersUS$1.13BUS$1.01B22.4×2.7×13.2×1.6×8.8%0.0×0.92

Forecasts

Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
5.00 CHF · Analysts' mean
EPS, year to Dec 2026
-0.13 · 1 analyst
Revenue, year to Dec 2026
223.3M · 2 analysts

Team and board

Officers

OfficerRole
Roland WandelerChief Executive Officer
Arno GroenewoudExecutive Vice President, Chief Financial Officer
Julien GanderExecutive Vice President, Chief Legal & Corporate Development Officer
Kevin BossDirector, Investor Relations
Amer JosephExecutive Vice President, Chief Medical Officer & Head of Global Clinical Development
Benjamin LimalExecutive Vice President, President of Europe & International Markets Region
Dominique Le TerrierExecutive Vice President, Head of Global Commercial Strategy & New Product Planning
Martine ClozelExecutive Vice President, Chief Scientific Officer & Head of Research

Board

DirectorRole
Jean-Paul ClozelChairman of the Board
Mathieu SimonVice-Chairman and Lead Independent Director

Events

Next results
Feb 25, 2027 (expected)

Calls

CallWhenStatus
Idorsia (SIX Swiss: IDIA) Q2 2026 Earnings CallThu, Jul 30, 2026 · 9:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q4 2025 Earnings CallThu, Feb 26, 2026 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q2 2025 Earnings CallWed, Jul 30, 2025 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q4 2024 Earnings CallTue, Mar 04, 2025 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q2 2024 Earnings CallThu, Jul 25, 2024 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q4 2023 Earnings CallTue, May 21, 2024 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q3 2023 Earnings CallTue, Oct 24, 2023 · 8:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q2 2023 Earnings CallTue, Jul 25, 2023 · 9:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q1 2023 Earnings CallTue, Apr 25, 2023 · 2:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q4 2022 Earnings CallTue, Feb 07, 2023 · 3:00 PM ETReplay
All 16 calls
CallWhenStatus
Idorsia (SIX Swiss: IDIA) Q3 2022 Earnings CallTue, Oct 25, 2022 · 1:00 AM ETReplay
Idorsia (SIX Swiss: IDIA) Q2 2022 Earnings CallTue, Jul 26, 2022 · 3:00 PM ETReplay
Idorsia (SIX Swiss: IDIA) Q4 2021 Earnings CallTue, Feb 08, 2022Replay
Idorsia (SIX Swiss: IDIA) Q2 2021 Earnings CallWed, Jul 28, 2021Replay
Idorsia (SIX Swiss: IDIA) Q4 2020 Earnings CallFri, Feb 05, 2021Replay
Idorsia (SIX Swiss: IDIA) Q2 2020 Earnings CallThu, Jul 23, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Oct 28, 2026 · After close−0.2%
Q2 2026Jul 29, 2026 · After close−5.0%
Q1 2026Apr 28, 2026 · Before open+4.8%
Q4 2025Feb 26, 2026 · Before open+5.3%
Q3 2025Oct 30, 2025 · Before open−1.6%
Q2 2025Jul 28, 2025 · After close−4.9%
Q1 2025Apr 30, 2025 · Before open+8.9%
Q4 2024Feb 5, 2025 · Before open−4.3%
Q3 2024Oct 29, 2024 · Before open+0.8%
Q2 2024Jul 25, 2024 · Before open+18.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 21, 2024 · Before open−2.0%
Q4 2023Mar 20, 2024 · After close−6.8%
Q3 2023Oct 24, 2023 · Before open−13.1%
Q2 2023Jul 25, 2023 · Before open−5.7%
Q1 2023Apr 25, 2023 · Before open−7.0%
Q4 2022Feb 7, 2023 · Before open−8.9%
Q3 2022Oct 25, 2022 · Before open+4.0%
Q2 2022Jul 26, 2022 · Before open+0.6%
Q1 2022Apr 26, 2022 · Before open−4.2%
Q4 2021Feb 8, 2022 · Before open−4.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck31 slidesNov 4, 2026
Sleep Europe 2026Conference22 slidesOct 23, 2026
Investor Presentation (October 2026)Investor deck48 slidesOctober 2026
Fact Sheet (September 2026)Fact sheet5 slidesSep 30, 2026
H1 2026 Earnings PresentationEarnings38 slidesJul 30, 2026
Fact Sheet (July 2026)Fact sheet5 slidesJul 29, 2026
Investor Presentation (July 2026)Investor deck51 slidesJuly 2026
Technical Presentation (March 2026)Technical23 slidesMar 31, 2026
Idorsia Pharmaceuticals — Q4 2025 Earnings PresentationEarnings23 slidesFeb 26, 2026
J. P. Morgan Healthcare Conference 2026Conference23 slidesJanuary 2026
Show 50 decks
DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck25 slidesNovember 2025
Investor Presentation (August 2025)Investor deck34 slidesAug 28, 2025
H1 2025 Earnings PresentationEarnings26 slidesJul 30, 2025
Fact Sheet (July 2025)Fact sheet23 slidesJul 30, 2025
H1 2024 Earnings PresentationEarnings13 slidesJul 25, 2024
Q1 2024 Earnings PresentationEarnings25 slidesMay 21, 2024
Investor Presentation (March 2024)Investor deck149 slidesMarch 2024
9M 2023 Earnings PresentationEarnings23 slidesOct 24, 2023
Fact Sheet (October 2023)Fact sheet7 slidesOctober 2023
H1 2023 Earnings PresentationEarnings21 slidesJul 25, 2023
Shareholder Meeting (May 2023)Shareholder meeting16 slidesMay 2023
Q1 2023 Earnings PresentationEarnings26 slidesApr 25, 2023
FY2022 Earnings PresentationEarnings39 slidesFeb 7, 2023
Fact Sheet (December 2022)Fact sheet6 slidesDecember 2022
Fact Sheet (December 2022)Fact sheet6 slidesDecember 2022
Technical Presentation (December 2022)Technical43 slidesDecember 2022
9M 2022 Earnings PresentationEarnings27 slidesOct 25, 2022
H1 2022 Earnings PresentationEarnings33 slidesJul 26, 2022
Technical Presentation (May 2022)Technical37 slidesMay 2022
Idorsia Pharmaceuticals — FY2021 Earnings PresentationEarnings42 slidesFeb 8, 2022
Technical Presentation (January 2022)Technical51 slidesJan 20, 2022
Idorsia Pharmaceuticals — H1 2021 Earnings PresentationEarnings21 slidesJul 28, 2021
Fact Sheet (July 2021)Fact sheet6 slidesJuly 2021
Technical Presentation (June 2021)Technical54 slidesJun 28, 2021
FY2020 Earnings PresentationEarnings24 slidesFeb 4, 2021
Investor Presentation (October 2020)Investor deck186 slidesOctober 2020
Fact Sheet (September 2020)Fact sheet6 slidesSeptember 2020
Technical Presentation (August 2020)Technical20 slidesAug 28, 2020
Idorsia Pharmaceuticals — H1 2020 Earnings PresentationEarnings19 slidesJul 23, 2020
Technical Presentation (July 2020)Technical21 slidesJul 6, 2020
Technical Presentation (April 2020)Technical25 slidesApr 20, 2020
FY2019 Earnings PresentationEarnings23 slidesFeb 6, 2020
H1 2019 Earnings PresentationEarnings37 slidesJul 23, 2019
Fact Sheet (April 2019)Fact sheet6 slidesApril 2019
FY2018 Earnings PresentationEarnings22 slidesFeb 7, 2019
Fact Sheet (February 2019)Fact sheet6 slidesFebruary 2019
H1 2018 Earnings PresentationEarnings25 slidesJuly 2018
Technical Presentation (June 2018)Technical24 slidesJune 2018
Technical Presentation (June 2018)Technical29 slidesJune 2018
Corporate Update (June 2018)Corporate update33 slidesJune 2018

This page holds 50 of 55 decks. Open Decks

Open Decks

Financings

RaiseDateIn US dollars
New Notes of Idorsia Investments SARL with 12% earn-out
Announced: CHF 72M
Use of proceeds: Launch capital for TRYVIO/JERAYGO: a focused US launch and phased commercialization in Europe and Canada
Oct 29, 2026US$86.78M
Private placement of registered shares (new and treasury shares)
Closed: CHF 65.6M raised · CHF 4 a share
Buyers: Jean-Paul and Martine Clozel (Offer Shares for an aggregate amount of up to CHF 10 million)
Insiders: Founding shareholders Jean-Paul and Martine Clozel committed to buy Offer Shares at the offer price for up to CHF 10 million, with a 180-day lockup
Use of proceeds: Strengthen balance sheet, accelerate QUVIVIQ commercial trajectory, advance pipeline, and general corporate purposes
Oct 10, 2025US$81.69M
Shares (equity line)
Update: raise
Use of proceeds: To further extend the cash runway into 2027
Aug 27, 2025
New money facility
Update: CHF 150M · Warrants at CHF 1.5
Use of proceeds: Extend cash runway to mid-2026
May 21, 2025US$181.85M
Private placement of shares
Announced: private placement
Use of proceeds: Additional capital to meet its obligations
Feb 26, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CHF

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue221.0M112.5M152.4M97.1M35.3M71.8M23.8M60.6M158.1M0
Cost of revenue38.4M179.6M7.15M6.27M18.0M381.1M438.5M370.1M161.9M18.1M
Gross profit182.2M-67.1M145.2M90.8M17.3M-309.3M-414.7M-309.5M-3.81M-18.1M
Research and development100.9M143.7M293.6M383.3M414.2M381.1M438.5M370.1M134.9M282.6M
Selling, general and administrative221.3M231.7M380.0M333.9M233.7M63.0M49.0M60.6M37.1M40.2M
Operating income-131.0M-232.0M-255.1M-803.0M-613.0M-410.6M-482.4M-371.1M-7.88M-322.8M
Depreciation and amortization17.4M17.9M19.0M19.8M18.0M18.9M19.7M19.6M10.1M18.1M
EBITDA-113.6M-214.1M-236.1M-783.1M-595.0M-391.7M-462.7M-351.5M2.17M-304.7M
Interest expense42.6M20.1M20.7M17.2M27.9M9.72M8.16M16.8M7.21M13.4M
Income before tax-105.6M-263.3M-294.3M-820.1M-634.8M-449.3M-485.2M-387.8M-15.1M-336.7M
Income tax6.12M434.0K3.67M7.81M-210.0K-4.16M9.45M-314.0K186.0K-2.05M
Net income-112.0M-263.8M-297.9M-827.9M-634.6M-445.1M-494.6M-386.4M-14.3M-335.1M
Earnings per share, basic-0.52-1.45-1.67-4.67-3.77-3.12-3.72-3.06-0.12-2.78

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents87.2M106.4M145.1M146.0M101.4M140.8M263.0M798.6M622.5M728.0M
Short-term investments18.0M12.8M330.3M936.8M869.2M480.1M125.1M218.3M
Receivables51.9M26.4M20.3M49.3M16.7M10.6M14.3M6.79M20.2M2.85M
Inventory82.1M62.6M59.1M35.8M21.7M12.9M17.7M10.6M-23.2M0
Current assets223.8M255.5M276.3M596.4M1.08B1.03B775.4M941.4M881.3M753.2M
Property, plant and equipment190.9M216.9M209.7M245.5M223.4M196.2M206.7M150.7M156.7M158.4M
Goodwill0
Total assets465.9M505.9M500.0M904.2M1.48B1.44B1.00B1.41B1.29B915.1M
Accounts payable17.5M35.2M19.9M25.4M26.9M11.1M8.76M7.13M4.25M10.7M
Current liabilities160.9M443.2M301.3M170.4M165.1M127.5M110.9M104.9M93.2M65.9M
Long-term debt1.15B931.8M931.0M1.13B1.09B587.4M579.0M570.8M364.7M293.4M
Total debt1.27B1.26B1.20B1.23B1.16B638.0M643.3M570.8M364.7M293.4M
Total liabilities1.60B1.72B1.47B1.57B1.38B849.9M839.9M749.1M552.4M407.2M
Shareholders' equity-1.14B-1.21B-968.7M-661.0M104.2M585.5M172.4M664.7M745.4M512.3M
Shares outstanding214.7M182.4M178.2M177.4M168.5M142.8M132.9M126.5M115.5M120.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-153.2M-370.2M-629.3M-859.1M-589.9M-364.7M-462.0M-352.8M95.5M-263.3M
Capital spending-13.8M-3.00M-9.40M-27.1M-30.9M-9.29M-19.0M-14.3M-7.66M-8.68M
Free cash flow-167.0M-373.2M-638.7M-886.2M-620.8M-374.0M-481.0M-367.1M87.8M-272.0M
Cash from investing4.16M305.1M632.6M743.9M-53.3M-607.1M-74.8M31.2M-476.0M-8.68M
Cash from financing132.1M26.1M-197.0K162.3M604.1M850.1M1.33M497.8M1.00B1.20B
Dividends paid-594.6M
Share buybacks84.4M-80.0K-197.0K360.0K-418.0K850.1M1.33M299.4M6.44M6.44M
Change in cash-17.8M-38.7M-946.0K44.6M-39.5M-122.2M-535.5M176.1M622.5M-272.0M

Open Financials

Cap table

Built by 6ix from Idorsia Ltd.’s releases · as of Oct 29, 2026

Common shares
269,779,588
Fully diluted
269,779,588

Fully diluted

LineShares
Common shares269,779,588

Share count over time

CountShares
Nov 22, 2026269,779,588

Open Cap table

Shareholders

Register

HolderSharesOf the companyChangeAs of
Jean-Paul Clozel58.5M23.3%Aug 14, 2026
Rubric Capital Management LP22M8.8%Apr 28, 2026
Rudolf Maag9M4.8%Jan 10, 2023
UBS Fund Management (Switzerland) AG7.74M3.3%Dec 10, 2025
Fidelity Mt. Vernon Street Trust7.57M3.0%Aug 12, 2026
Georges Gaspard3.24M2.5%May 17, 2019
BlackRock, Inc.No changeOct 1, 2026
Fabrice EvangelistaOct 20, 2025
Idorsia LtdAug 14, 2026
Johnson & JohnsonJun 24, 2026
All 13 holders
HolderSharesOf the companyChangeAs of
UBS Group AGNo changeOct 19, 2026
The Goldman Sachs Group, IncNo changeOct 13, 2026
FMR LLCOct 13, 2025

Funds

HolderSharesValueChangeAs of
Fidelity Growth Company Fund4.67MUS$26.7MNo changeMay 31, 2026
Select Biotechnology Portfolio2.17MUS$12.4MNo changeMay 31, 2026
Fidelity Growth Company K6 Fund1.36MUS$7.79M−12,521May 31, 2026
iShares Core MSCI EAFE ETF1.23MUS$9.29M+399KJul 31, 2026
Fidelity Series Growth Company Fund914KUS$5.23M−139KMay 31, 2026
iShares MSCI EAFE Small-Cap ETF671KUS$5.08M+62,766Jul 31, 2026
Columbia Variable Portfolio - Overseas Core Fund420KUS$3.56MNewJun 30, 2026
Vanguard Total International Stock Index Fund398KUS$3.02MNewJul 31, 2026
iShares Core MSCI Total International Stock ETF188KUS$1.42MNewJul 31, 2026
American Beacon IMC International Small Cap Fund160KUS$1.21MNewJul 31, 2026
All 33 holders
HolderSharesValueChangeAs of
iShares Core MSCI International Developed Markets ETF128KUS$966KNewJul 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF117KUS$993K−120Jun 30, 2026
Fidelity Total International Index Fund114KUS$864K+30,052Jul 31, 2026
College Retirement Equities Fund - Total Global Stock Account107KUS$908KNo changeJun 30, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund102KUS$777KNewJul 31, 2026
iShares Core MSCI Europe ETF95,951US$727K+16,925Jul 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF79,279US$675K+821Jun 30, 2026
Schwab International Opportunities Fund68,923US$522KNewJul 31, 2026
Vanguard European Stock Index Fund64,880US$492KNewJul 31, 2026
Fidelity SAI International Small Cap Index Fund54,030US$409K+11,658Jul 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio41,099US$350KNewJun 30, 2026
The Gabelli ABC Fund27,000US$229KNo changeJun 30, 2026
Vanguard Total World Stock Index Fund22,712US$172KNewJul 31, 2026
iShares MSCI Europe Small-Cap ETF20,245US$153K+2,493Jul 31, 2026
iShares International Small-Cap Equity Factor ETF14,304US$108K+290Jul 31, 2026
Columbia Global Opportunities Fund12,403US$93,966NewJul 31, 2026
iShares Neuroscience and Healthcare ETF10,423US$78,965+858Jul 31, 2026
iShares MSCI World Small-Cap ETF9,017US$51,403−3,008May 31, 2026
State Street(R) SPDR(R) Portfolio Europe ETF8,693US$73,982+3,270Jun 30, 2026
Enterprise Mergers and Acquisitions Fund2,200US$18,692No changeJun 30, 2026
The Gabelli Global Rising Income and Dividend Fund1,000US$8,496No changeJun 30, 2026
Avantis International Equity Fund580US$3,306No changeMay 31, 2026
Avantis Responsible International Equity ETF521US$2,970+5May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Amer JosephExecutive Vice President, Chief Medical Officer & Head of Global Clinical Development · Since May 1, 2026
Arno GroenewoudExecutive Vice President, Chief Financial Officer · Since at least Oct 29, 2026
Benjamin LimalExecutive Vice President, President of Europe & International Markets Region · Since at least Jul 27, 2026
Dominique Le TerrierExecutive Vice President, Head of Global Commercial Strategy & New Product Planning · Since at least Nov 5, 2026
Jean-Paul ClozelChairman of the Board · Since at least Aug 11, 2026
Julien GanderExecutive Vice President, Chief Legal & Corporate Development Officer · Since at least Nov 5, 2026
Kevin BossDirector, Investor Relations · Since at least Oct 29, 2026
Martine ClozelExecutive Vice President, Chief Scientific Officer & Head of Research · Since at least Jun 1, 2026
Mathieu SimonVice-Chairman and Lead Independent Director · Since at least May 6, 2026
Roland WandelerChief Executive Officer · Since Oct 1, 2026

Open People

Log in to ask 6ix AI your own questions about Idorsia Ltd.